Here's why you should never add sugar to your aam panna
Aam panna, a tangy and refreshing summer drink made from raw mangoes, is a staple in many Indian households during the scorching summer months. Umang Malhotra, clinical dietitian at Fitelo, shared that it is prepared with raw mango pulp, mint, roasted cumin, black salt, and sometimes a bit of jaggery. This vibrant green drink is cherished not just for its taste but also for its cooling, hydrating, and electrolyte-restoring properties. It also helps reduce body heat, and aid digestion—making it a natural remedy against the harsh effects of summer.
To cut through the acidity, people tend to add a pinch of sugar into the mix. However, Malhotra said that adding refined white sugar to aam panna can quietly undo many of its health benefits.
'While sugar might enhance the flavor and appeal to those with a sweet tooth, it actually works against the body's hydration mechanism. Refined sugar increases insulin levels, which in turn causes the kidneys to flush out more sodium and water. This results in a net loss of electrolytes and fluid ironically, the very thing aam panna is meant to replenish,' he said.
In fact, he added that sugar causes an osmotic effect in the body, drawing water out of cells into the bloodstream to dilute excess glucose, thereby dehydrating cells and tissues at a deeper level. 'Excessive sweetness dulls the drink's ability to soothe the gut and can even contribute to bloating and indigestion,' said the dietitian.
To truly enjoy the benefits of aam panna, Malhotra recommended that it is best to avoid refined sugar altogether. Instead let the natural tang of the mango shine through. Adding ingredients like roasted cumin, mint, and black salt not only enhances the flavor but also boosts the drink's digestive and cooling properties.
Here's a quick recipe to enjoy this cooling drink:
Raw mango – 500 grams
Sugar – 500 grams
Mint leaves – 1 cup
Sweet tulsi leaves – 1/2 cup (optional)
Salt – 2 tsp
Black salt – 2 tsp
Roasted cumin – 2 tsp
Black pepper – 1 or 2 tsp
Cardamom – 7 to 8
Ginger – 1 inch piece
Finally take 2 to 3 tbsp mango panna in a glass, add water and some ice to it and the mango panna is ready to be served.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
4 hours ago
- Time of India
How to make high-protein and nutrition-loaded breakfast cereal
boxed cereals are a common breakfast choice, especially for children and busy adults. However, many of these cereals are loaded with refined sugars and artificial additives, which can lead to increased triglyceride levels and lower good HDL cholesterol. Breakfast is considered the most important meal of the day. A good and healthy breakfast can make your day fully energised and healthy. But in today's fast-paced environment, everyone is busy with their work and lives and is always looking to save time. During these times, the metaphor "Time is money' is more true than ever. To save time, many of us choose to compromise on things that also include our diet choices. Over time, many people have moved toward ready-to-make morning breakfasts. The most popular ready-to-make breakfast has been cereals. Cereals are ready to eat and easy to prepare for breakfast. Cereals include ingredients such as oats, corn, wheat, rice, barley, and millets. Most breakfast cereals are fortified with vitamin B12, making them one of the simplest sources for vegetarians and vegans. Over the years, cereal has become a regular part of the Indian diet. But cereal's history goes back hundreds of years. Modern-day cereals were invented by Dr. James Caleb Jackson, who created the first ready-to-eat cereal in 1863. Later, Dr. John Harvey Kellogg and his brother Will Kellogg invented corn flakes in 1894, which became a worldwide phenomenon and still remain relevant to this day. Nowadays, our daily lives have become more and more engaged in work. It has become hard to differentiate between work life and personal life and it has severely affected our food choices. With time, more and more people are shifting and have started to consume ready-made food. The most common time to consume ready-made food has become breakfast. Most people have started eating more ready-to-make food during breakfast to avoid spending time in the kitchen and to concentrate on preparation for the day ahead. Boxed cereals have become a top choice for ready-to-make meals as they are easy to prepare and taste delicious. But eating boxed cereals has its own negative effects such as: Boxed cereals contain high levels of added sugar. Consuming this high amount of sugar can lead to a quick energy spike, followed by a crash during the day. It is also not good for someone already suffering from a health condition such as diabetes or obesity. Boxed cereals not only contain added sugar but also refined carbs, which could lead to a rapid spike in blood pressure. They also contain preservatives which could lead to multiple health problems like liver and kidney failure in the future. Rating high on the convenience factor, breakfast cereals, extremely popular in the West, have now made their way to the table of our homes as well. But you don't have to worry once you become aware of the dangers of boxed cereals. Here are alternative ways to make nutrition-loaded breakfast cereals you can eat: Overnight Protein Oats Overnight protein oats are a high-protein breakfast and an ideal choice for gym lovers. They are made by soaking oats in a liquid like water or milk, along with a scoop of protein powder, overnight. You can also add extra ingredients such as cinnamon, chia seeds, or others. After soaking overnight, it is ready to eat in the morning. It's convenient, filling, and keeps you energized for hours. Homemade Granola Cereals Homemade granola cereal is a crunchy, customizable, and protein-rich breakfast or snack you can enjoy every day. Granola has no preservatives and is rich in fiber and protein. It is made of rolled oats, nuts (almonds, walnuts, cashews), seeds (sunflower, pumpkin, chia), honey or jaggery syrup, vanilla extract, and salt. It is then baked in the oven at 160 degrees. Once cooled, it's ready to eat and is often served with yogurt. Chia Seed Protein Cereals Chia seed protein cereal is made with 3 tablespoons of chia seeds, 1 cup of milk or 2–3 tablespoons of yogurt, and 1 scoop of protein powder. Stir the ingredients well and let them soak overnight. By morning, the chia seeds will absorb the liquid and have a pudding-like texture. You can top it with nuts and fruits for added nutrition and taste. It's a great plant-based, nutrient-dense breakfast. Savory Protein Cereal Savory protein cereal is like an all-in-one breakfast. It's as light as traditional cereal, has the nutrition of a protein bar, and is perfect for spicy food lovers. It's made of flattened rice (poha) and roasted chana. You can add protein by including sprouted moong or crumbled Indian cottage cheese (paneer), then temper and mix it. Savory protein cereal dishes are unique and different from regular cereal—ideal if you're looking for something spicy and different for breakfast. These types of natural homemade cereals prevent the body from getting exposed to added sugar, preservatives, and chemicals found in boxed cereals. Morning breakfast plays a crucial role in the daily routine as it fuels the body for the day ahead. Having a nice and healthy breakfast is essential to keep your mood fresh and your body active. One step to a healthier you—join Times Health+ Yoga and feel the change
The Hindu
5 hours ago
- The Hindu
Misinformation a bigger threat than COVID-19 uptick
The reported cases of COVID-19 in India have risen from less than a few a day to a few 100 a day since mid-May 2025. Wastewater surveillance data from Indian cities have also reported an increased SARS-CoV-2 viral load. All this has resulted in heightened media and public attention because of the COVID-19 experience in 2020-21. A similar uptick in COVID-19 cases has also been reported from some other countries and regions of the world which includes Singapore, Hong Kong, Thailand and South Korea. Is there a new variant circulating? Are there reasons to worry? The current uptick in cases is being linked to the most common SARS-CoV-2 variant currently circulating, JN.1, a descendent of the Omicron variant (BA.1.529). Omicron has been the last variant of concern of SARS-CoV-2, first reported in November 2021. Since then, even though a few sub-variants or sub-lineages of Omicron have emerged, there has not been any new variant of concern, in any part of the world. The current dominant variant, JN.1 (also called Pirola) is not new and was first reported in August 2023 in Luxembourg and has been reported from India since November-December 2023. A few sub-lineages of JN.1, such as LF.7 and NB.1.8, have also been reported. But till now, there have not been any major clinical differences with the parent variant. Epidemiological facts Why this uptick? The answer lies in three epidemiological facts. First, any new virus stays for long once it enters the population, possibly forever. SARS-CoV-2 is omnipresent in India and other countries, even when no new infections are being reported. In September 2020, Moriyama M. and colleagues discussed in the scientific journal, Annual Review of Virology, that the seasonality of respiratory viruses has been recognised for thousands of years, and that the annual epidemics of the common cold and influenza disease are the most known proof. The contributing factors for seasonality are environmental parameters such as temperature and humidity, human behaviour and crowding, and changes in viral genes to alter virus stability and transmission rates. SARS-CoV-2 is a respiratory virus and is likely to have a seasonal pattern. It is just that, till now, the pattern in a rise in COVID-19 has not been established. Though some data from Singapore indicate that COVID-19 cases rise every six to nine months, the seasonality may vary from one country to another. In India, after the Omicron wave in January 2022, there were upticks in COVID-19 cases in early 2023 (due to the Omicron Sub-lineage XBB.1.16), then in December 2023 and January 2024, and then in July-August 2024. There is a fresh uptick now, from May 2025. Therefore, a seasonal pattern of COVID-19 surge, every eight to 10 months might be an emerging pattern for India. It is worthwhile to note that the number of reported cases in most seasonal surges has been relatively small and clinical disease has become mild to milder. Also read | Wastewater surveillance shows increasing COVID-19 viral load Second, SARS-CoV-2 is a type of RNA virus, which is known to have more frequent mutations and genetic changes than other types of viruses. Though the key variant continues to be JN.1, there have been some new sub-lineages, which might be behind the uptick. Third, the uptick in COVID-19 cases in India is real but also due to enhanced COVID-19 testing and surveillance, following reports of COVID-19 cases in neighbouring countries. Increased testing means more people are being tested and, thus, detection. So if the Indian population has 'hybrid immunity' from natural infection and through vaccines, and if this is not a new variant, why is there still an uptick? The answer is neither natural infection nor vaccine-induced protects from fresh infection. Immunity does protect from moderate to severe diseases and deaths. The cases or infections are a mere indicator that a person carries SARS-CoV-2 in their nose and throat. However, immune protection will ensure that people do not get sick or have severe illness. As of now, no serious cases of illness are being reported. Numbers in perspective The current uptick seems to be getting disproportionately high attention. Even with the spike, 200 to 300 new COVID-19 cases a day in India translates to one new infection for every 45 lakh to 70 lakh population. We are not hearing about hospitalisations due to COVID-19 and the deaths being attributed are one or two in a day. Let us put these numbers in perspective. The daily infections due to other illnesses are in thousands and lakhs every day. For example, every day, 8,000 new cases of tuberculosis (TB) are being reported in India. If we think in terms of deaths, every day, nearly 30,000 people in India die due to old age and other health conditions. Every day, an estimated 900 people die due to TB, a preventable and treatable health condition; another 390 due to influenza virus illness and another 310 deaths due to the relatively unheard but widely prevalent vaccine preventable Respiratory Syncytial Virus (RSV) disease. Air pollution and respiratory illnesses cause manifold illnesses and deaths. In this backdrop, COVID-19 is just another illness that is much less severe than other health issues which need greater priority. One reason why it is getting attention is because of the continuous use of old but not so relevant tracking parameters such as 'active cases', which give a falsely high number of COVID-19 cases. The approach of 'active cases' was acceptable early in the COVID-19 pandemic, when infectiousness lasted one to two weeks as the virus was novel and there was no immunity against virus in people. Therefore, after the infection, the immune system needed one to two weeks to get activated and clear the virus, prolonging the process. However, five years since then, most individuals have immunity from either vaccines or natural infections to mount a quick and effective defence and thus, be non-infectious in a day or two as well. Therefore, counting everyone who tested positive as an active case does not make sense. On vaccination There is no need for an additional COVID-19 vaccine dose. In the first three years of COVID-19 (2020-22), the Indian population (all age groups) had been exposed to various variants of SARS-CoV-2 including Omicron. Alongside this, nearly all adults received two or more shots of COVID-19 vaccines. Therefore, the population in our country has 'hybrid immunity' against SARS-CoV-2. Most people were exposed to the Omicron variant in December 2022 and January 2023. And JN.1, the circulating dominant variant, is from the Omicron family. It is likely that antibody levels would have gone down and there is waning immunity. Thus some immune escape to new sub-variants is possible. However, the human immune system has specialised cells called 'memory cells' which are largely undetectable but are programmed to respond to future infections and are likely to protect against future severe illness. There is no new variant of concern to believe immune escape, as of now. Scientifically, there is no need and thus no recommendation for additional shots of COVID-19 vaccine for the Indian population. COVID-19 is not a concern and the prevention and the treatment of any pre-existing health condition is much more effective than 'additional COVID-19' shots. Thus, those with high risk should get vaccinated with flu and other age-appropriate recommended vaccines to prevent any comorbidity. The current uptick in COVID-19 in Asia and India seems to follow an emerging seasonal pattern of SARS-CoV-2. There does not seem to be any reason for worry. All that is needed is for the government to keep a watch and monitor the trends. The Infodemic and misinformation could be a bigger threat than a minor uptick in COVID-19 cases. For India, for both government and citizens, there needs to be a balanced approach — neither underestimating the threat nor spreading panic. One important tool in this is not to spread unverified messages and rumours. There is a need for a rational, epidemiological and balanced approach in reporting and responding to the current and future seasonal spikes in COVID-19. If we continue to treat every spike as an impending 'wave' and as a 'false alarm', it will strain the health system and workforce, resulting in response fatigue and undermining credibility. Responses to COVID-19 surges must be rational, proportionate and reflective of epidemiological reality. Current evidence is that from now, COVID-19 could be treated like any other mild respiratory illness. Dr. Chandrakant Lahariya is a practising physician and a leading epidemiologist and global health expert, who has nearly 17 years of professional work experience with the World Health Organization and other UN agencies
Time of India
6 hours ago
- Time of India
Glenmark's blood cancer drug ISB 2001 shows promising results in trial
Ichnos Glenmark Innovation, a clinical stage biotechnology company focused on oncology, has announced promising results for an innovative drug used for the treatment of relapsed or refractory multiple myeloma (RRMM), a rare form of blood cancer that affects plasma cells in bone marrow. Coded ISB 2001, the drug demonstrated an overall response rate (ORR) of 79% in a Phase 1 global study based on finding from patients who were administered a recommended dose. Patients who had exhausted other advanced treatments, such as CAR-T cell therapy and bi-specific antibodies, also showed encouraging results when given the drug. IGI is an alliance between the New York-based scientific research group Ichnos Sciences and Indian drug maker Glenmark. Senior haematologists say that the drug could potentially be an important candidate in the treatment of patients - who exhaust other therapy options due - to its unique mechanism of engaging the body's T cells (that are a vital part of the immune system) along with the attacking two sites on the tumour cell. Dr Shyam Rathi, consultant, clinical hematology, PD Hinduja Hospital & Medical Research Centre in Mumbai, said: 'It can definitely be a game changer in treatment of multiple myeloma which keeps relapsing thus exhausting treatment options quickly. This new drug looks very attractive because it targets two different sites on the cancer cell and it engages the body's own T-cells.' 'We have existing bi-specific antibodies where the target is only one antigen and they develop resistance very fast. However, ISB 2001 targets the two sites on the cancer cell and we expect some better results. It looks exciting in the future.' In lay terms, ISB 2001 binds to three sites on the cancer tumour. First, the ISB 2001 activates the CD-3 T-lymphocytes, which are the cells that have the natural attacking power against tumour cells. Next, it binds to two additional sites. The first is BCMA (a protein found on myeloma cells), which is the target for bi-specific antibodies but there is also CD38, which is the binding site of the widely prescribed drug called daratumumab, branded as Darzalex by Johnson & Johnson. Glenmark, which is pinning a lot of hopes on the new drug, is in advanced talks with multiple global Big Pharma companies for a licensing deal, Chairman and Managing Director Glenn Saldanha told analysts over an earnings call recently. 'The discussions are progressing really well, and we anticipate a positive outcome very quickly,' said Saldhana. He said a deal for ISB 2001 will 'really be transformational for Glenmark' and 'will overshadow anything else that we are doing in the near term.' 'You should see some visibility around a licensing deal pretty quickly.' Last year Ichnos and Glenmark entered into a partnership for discovery of cutting-edge therapies, specifically to treat blood related cancers and malignancies like multiple myeloma. The global market for multiple myeloma treatment is seeing a surge. The business for such drugs is expected to rise to $33 billion by 2030, up from $23.5 billion in 2023,according to Bloomberg Intelligence estimates. Hang Quach, professor of haematology at the University of Melbourne noted that the data presented on ISB 2001 highlighted the 'remarkable anti-myeloma activity of this first-in-class trispecific antibody-T cell engager in heavily pre-treated RRMM patients' including those who have exhausted other approved therapies. According to Quach, ISB 2001 has the potential 'to redefine the treatment landscape for multiple myeloma, offering new hope for patients with limited therapeutic options.' The drug demonstrated a favourable safety profile throughout the dose-escalation phase, with no dose-limiting toxicities (DLTs) reported.
